Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;79(6):1199-1208.
doi: 10.1002/jpn3.12392. Epub 2024 Oct 23.

Natural course and outcomes of children with ubiquitin-specific protease 53 (USP53)-related genetic chronic cholestasis

Seema Alam  1 , Bikrant Bihari Lal  1 , Aathira Ravindranath  2 , Ashish Bavdekar  3 , Nirmala Dheivamani  4 , Pandey Snehavardhan  5 , Aashay Shah  6 , Parijat Ram Tripathi  7 , Aabha Nagral  8   9 , K P Srikanth  10 , Ira Shah  11 , Somashekara Hosaagrahara Ramakrishna  12 , Arya Suchismita  13 , Yogesh Waikar  14 , Vaibhav Shah  15 , Zahabiya Nalwalla  16 , Karunesh Kumar  17 , Arjun Maria  18 , Anupam Sibal  17 , Viswanathan M Sivaramakrishnan  19 , Nishant Wadhwa  18 , A Ashritha  1 , Vikrant Sood  1 , Rajeev Khanna  1 ; Indian PFIC Registry
Affiliations

Natural course and outcomes of children with ubiquitin-specific protease 53 (USP53)-related genetic chronic cholestasis

Seema Alam et al. J Pediatr Gastroenterol Nutr. 2024 Dec.

Abstract

Ubiquitin-specific protease 53 (USP53) is essential for formation of cellular tight junctions and variations in this gene disrupt the tight junctions, resulting in cholestasis. We describe the clinical manifestations and outcomes of patients with USP53 mutations from the Indian progressive familial intrahepatic cholestasis registry. All 29 patients who harbored mutations in the USP53 gene either in the homozygous, compound heterozygous, or heterozygous state and presented with cholestasis were included. USP53 variants related to cholestasis had good outcomes, with native liver survival in 82.7%, whereas 17.3% required liver transplantation. Jaundice developed in 93% and within 3 months of age in 48.8%. Jaundice resolved in 21 (72.4%). Pruritus 76% at a median age of 7 months (severe in 10/22, 45% and refractory to medical therapy in 4, 18.1%). Majority of them (82.7%) had biallelic mutations. Protein-truncating mutations were present in 20 (69%) and missense mutations in 9 (31%). No correlation was found between the genotype and the outcome.

Keywords: Indian PFIC registry; jaundice; progressive familial intrahepatic cholestasis (PFIC); pruritus.

PubMed Disclaimer

References

REFERENCES

    1. Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2017;64:154‐168.
    1. Monies D, Abouelhoda M, Al Sayed M, et al. The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes. Hum Genet. 2017;136:921‐939.
    1. Shagrani M, Burkholder J, Broering D, et al. Genetic profiling of children with advanced cholestatic liver disease. Clin Genet. 2017;92:52‐61.
    1. Maddirevula S, Alhebbi H, Alqahtani A, et al. Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants. Genet Med. 2019;21(5):1164‐1172.
    1. Lal BB, Alam S, Sibal A, et al. Genotype correlates with clinical course and outcome of children with tight junction protein 2 (TJP2) deficiency‐related cholestasis. Hepatology. 2024;80(3):511‐526. doi:10.1097/HEP.0000000000000828

Substances

Supplementary concepts

LinkOut - more resources